Get started

IPO

UBER - Don't buy the dip, yet...Analyst earnings review UBER had third-quarter earning results above the top- and bottom-line S&P Capital IQ consensus expectations. However, we still expect losses in Uber Eats, along with more aggressive investments in ATG, to delay Uber’s first full-year adjusted EBITDA until 2022. Analyst target: $58 Uber's IPO lock-up period over!! Tomorrow November 6th, 2019 . Investors who got in at the IPO, can now start selling their shares. We could see a potential drop, as it has happened with other IPO's so far.
NYSE:UBERShort
by dorfmanmaster
BYND bullish cypher and demand zone after the earning CRASH.BYND actually had a nice earning report yesterday while as the locked up period had ended, it was sold-off fiercely. Still, alternative-meat industry has lots of rooms to be imagined, to look for a careful buying opportunity isn't a crazy idea! Here we got this bullish cypher pattern and little demand zone structure near 68.00 spot, I would be interested in the long with 2 possible outs: 1. short-term: below 60.00 (a 10%-risk trade) 2. long-term: below 45.00 (a 30%-risk investment) By now the market still need to digest the selling pressure so I'm in no hurry to get in the trade, to wait for a clearly reversal sign there as a final confirmation of this idea is necessary! Let's see how it goes yo!
NASDAQ:BYNDLong
by Trader_Joe_Lee
2
CloudFlare: IPO DarlingI have a hard time analyzing IPOs because there's very little technical data to analyze, but I do have some personal industry experience with CloudFlare. The sentiment and fundamentals for this firm are strong, and that's all you can analyze with IPOs! They're a tech company. They're positioned to eat Akamai's dogfood, too. They're not yet profitable, but that's common for a young company in the technology and internet space. They've increase revenue 43% from 2017 to 2018, and their racking up new paid customers like it's going out of style. Take a look at the data for yourself: www.forbes.com medium.com
NYSE:NETLong
by chuckination
8
MCOA Long Bullish IndicatorsProceed with caution, this is not financial advice. I merely intend to inform you of my observations and of my personal position. I am of course biased as I have already chosen to invest, but I feel bad not letting others in on this lesser known stock with very bullish outlooks. I recognize bullish indicators in my Stoch RSI and in candle analysis. Also, the company is coming out with several new products, new partnerships, and spent 38 million in R&D last year, likely for their upcoming "Viva Buds" app wherein users can order cannabis to their door on a subscription basis. They purchased 20% and issued one million in stock of a local cannabis distributor to the CA area. The fact that they issued so much stock to business partners suggests to me that they expect its price to increase. I would assume they also spent money on app development, but far less. This means that this stock is a bunny waiting to hop. In 2000 before the crash with prices of over $600, lots of skips and hops after declining to 30 and below. Now at a price of .0059, where can the price lie in even 6 months from now when the app is at market? Since they invested in an existing distributor, the infrastructure is already there. Now, their software will enable the monetization of all of their R&D from last year. They already have a CBD lotion and other products at market. On top of that, today they filed for a reverse stock split. I am personally accumulating as much of this stock as possible while it is at what is essentially a round of public capital raise; a re-IPO if you will. Be careful, Best.
OTC:MCOA
by primroseverglade
Revolve will establish new channelRevolve has had a rocky time since its IPO, with lots of volatility and several breaks below critical trend lines. However, this company is profitable, undervalued, and highly rated, and in my opinion it's still a great value. With Revolve having breached the bottom of its parallel channel today, it's likely to establish a new channel. I've drawn a couple possible channels and some trend lines, and I've marked the breakout zones with the play for each zone. I've also marked support and resistance from all-time highs, and you can also see the high-volume support node at 35.27. Currently I'm playing this long on the basis of that volume support node.
NYSE:RVLVLong
by ChristopherCarrollSmith
3
Stitch Fix poised for a turnaroundStitch Fix is at support from a high-volume node on the volume profile and from its 50-day moving average. It also has some RSI support around 38. The stock just got some big analyst upgrades from Zacks and Goldman, which could serve as upside catalysts. The Internet retail sector is currently outperforming the S&P 500. S&P Capital IQ rates Stitch Fix as undervalued, with stable growth potential. Overall, both fundamentals and market sentiment are looking up for the stock. However, Stitch Fix has some downward momentum, so it could fall through the 50-day MA before rebounding from 200-day MA support near 26. I don't expect it to fall any further than that, but in the worst-case scenario we could get as low as the high-volume node at 23.
NASDAQ:SFIXLong
by ChristopherCarrollSmith
ZOOM - Bullish analyst ratingOne of this year's hottest IPOs is still winning over new fans. Dmitry Netis at Stephens is initiating coverage of Zoom Video (ZM) with a bullish overweight rating . The analyst's price target of $115 suggests that there's 26% of upside from current levels, an encouraging goal for the provider of video-conferencing solutions for enterprises that has already soared 153% since going public at $36 in April through Thursday's close. ---News reported by Rick Munarriz, The Motley Fool / Yahoo Finance
NASDAQ:ZMLong
by dorfmanmaster
1
Adaptive Biotechnology (MSFT & Genentech partner)"Microsoft and Adaptive Biotechnologies announce partnership using AI to decode immune system; diagnose, treat disease" They also have a partnership with Genentech (January 2019) ADPT - Adaptive Biotechnology IPO: June 27th 2019 - open @$39 (above current price) Vision: We aim to improve people’s lives by translating the scale and precision of their adaptive immune systems into products to help diagnose, treat, and monitor disease. Great risk reward with an entry right now. If we break the IPO low @36.2, I would recommend exiting part of your position. Happy trading! dorfmanmaster P.S: I think this is a short-term, not to mention long-term good investment. I recommend looking for their research on cellular therapy.
NASDAQ:ADPTLong
by dorfmanmaster
Akerna $KERN Coming In That Buy Zone. Fresh IPO (kind of).Akerna coming into that buy zone. Stock IPOed (actually it was a SPAC) at around $11 after doing their last private placement at $10.21. As this is a recent IPO (of sorts) and a cannabis company, I expect this will eventually shake out at 2x the IPO price (around $20) so buy on dips. Why 2x IPO price? Look at high flyers Zoom $ZM, Beyond Meat $BYND, Crowdstrike $CRWD, all trading at about 2x IPO price, based on hype, growing markets, and sales growth. Akerna is Cloud + Payments + Cannabis. They have an ERP software for cannabis supply chain / growers / dispensaries. All the buzzwords. Not sure 100% if the company has a legit future (need to do more research), but certainly I think this thesis is enough to put it on your watchlist.
KLong
by behindthebid